REGENXBIO Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 18 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-08-25: Reporting owner Ciongoli Gregory Austin; Form 4; Security Stock Options (Right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-07-02: Reporting owner PAKOLA STEVE; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-07-01: Reporting owner PAKOLA STEVE; Form 4; Security Stock Options (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2026-05-29: Reporting owner Tasse Daniel; Form 4; Security Stock Options (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
RGNX insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-08-25 | Ciongoli Gregory Austin Director | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +69,609 69,609 owned after | $8.91 exercise price | $8.91 | 2026-08-27 |
| 2026-07-02 | PAKOLA STEVE Officer (Chief Medical Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,161 64,812 owned after | $7.86 exercise price | $13.28 | 2026-07-06 |
| 2026-07-01 | PAKOLA STEVE Officer (Chief Medical Officer) | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −36,725 66,973 owned after | $7.86 exercise price | $13.09 | 2026-07-01 |
| 2026-05-29 | Tasse Daniel Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | STUMP DAVID C Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | Zachary Jennifer Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | Mills Kenneth T. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | MIGAUSKY GEORGE V Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | KARABELAS ARGERIS N Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | Glucksmann Alexandra Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | Fox Allan M. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-05-29 | Bennett Jean Director | 4 | Stock Options (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +46,600 46,600 owned after | $7.01 exercise price | $7.01 | 2026-06-02 |
| 2026-01-27 | Mills Kenneth T. Director | 4 | Stock Options (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −225,000 225,000 owned after | $13.09 exercise price | $13.41 | 2026-01-29 |
| 2026-01-06 | PAKOLA STEVE Officer (Chief Medical Officer) | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,402 35,402 owned after | $14.18 exercise price | $14.18 | 2026-01-08 |
| 2026-01-06 | Malzahn Craig Officer (Chief Technology Officer) | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +35,402 35,402 owned after | $14.18 exercise price | $14.18 | 2026-01-08 |
| 2026-01-06 | Simpson Curran Director, Officer (Chief Executive Officer) | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +233,651 233,651 owned after | $14.18 exercise price | $14.18 | 2026-01-08 |
| 2026-01-06 | Christmas Patrick J. Officer (Chief Strategy & Legal Officer) | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,650 39,650 owned after | $14.18 exercise price | $14.18 | 2026-01-08 |
| 2026-01-06 | Chan Mitchell Officer (Chief Financial Officer) | 4 | Stock Options (Right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +39,650 39,650 owned after | $14.18 exercise price | $14.18 | 2026-01-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |